TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05251948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is administered orally twice daily on Days 1-14 of each 21 day cycle. Treatment for up to six cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin is administered by IV infusion on Day 1 of each 21 day cycle. Treatment for up to six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is administered by IV infusion on Day 1 of each 21 day cycle. Treatment for up to six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab is administered by IV infusion on Day 1 of each 21 day cycle.
Study: NCT04584983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual prescribed intralipid (UL) regimen
Description: Intralipid will be started at 1 g/kg/day and routinely advanced by 1 g/kg/day each day to a max of 3 g/kg/day as per usual clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: restricted prescribed intralipid (RL) regimen
Description: Intralipid will be started at 0.5 g/kg/day and routinely advanced by 0.5 g/kg/day each day to a max of 1.5 g/kg/day (half rate of usual clinical practice).
Study: NCT05425459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corvia Atrial Shunt System / IASD System II
Description: The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Description: Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
Study: NCT05642884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-modal Exercise Regimen
Description: Participants will undergo a total of 16 sessions over 8 weeks. Each therapy session will comprise of patient education, including facilitated goal planning, promotion of physical activity and safe exercise guideline, followed by 30 minutes of preferred aerobic activity such as walking or biking.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary Guidelines
Description: Participants will be contacted once a week to review dietary recommendations per the 2022 American Cancer Society guidelines for cancer survivors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Guidelines
Description: Participants will be contacted once a week to review dietary recommendations per the 2022 American Cancer Society guidelines for cancer survivors.
Study: NCT06254950

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-279
Description: TAK-279 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-279 placebo-matching capsules.
Study: NCT05139004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo AHSCT
Study: NCT06299462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide injection
Description: Cyclophosphamide 50 mg/kg on days +3 and +4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide injection
Description: Cyclophosphamide 50 mg/kg on days +3 and +4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG 2.5±1.5
Description: ATG 2.5 mg/kg on day -1 ± 1.5 mg/kg on day -2
Study: NCT05414552

Intervention type: DRUG
Intervention: ECP
Description: Treatment with ECP for irAEs with 2 cycles performed on two consecutive days, for the first 4 weeks repeated every week, and from week 5 to 12 repeated every two weeks
Study: NCT06347263

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Entire papilla preservation technique
Description: Minimally invasive periodontal surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Entire papilla preservation technique
Description: Minimally invasive periodontal surgery
Study: NCT05239767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: We will administer oral NSAIDs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: We will administer oral NSAIDs
Study: NCT05202847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed radiofrequency ablation to modifined points group
Description: Point 1 place 10mm higher than the boundary between Femur's medial epicondyle and shaft. The 2nd point is targeted 20mm above the patella. Point 3 is targeted 10mm above the femur lateral epicondyle and shaft boundary. At point 4, find the boundary position between the tibia epicondyle and the shaft in the AP view and move it superolateral by 10 mm to target the central part of the medial shaft of the tibia and perform the main touch. Point 5 targets the center of the fibular head.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency ablation to conventional points group
Description: Under AP view X-ray fluoroscopy, enter the cannula into the tunnel view until reaching the bone, reaching the border of the shaft and epicondyle, then stop the cannula tip at the anterior 2/3 junction in the lateral view. A total of three target points are the boundary position between the femur medial epicondyle and the shaft, the boundary position between the femur lateral epicondyle and the shaft, and the boundary position between the tibia meidal epiconcyle and the shaft. Subsequent procedure will be proceed same as Arm 1
Study: NCT04929652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib,Camrelizumab,Irinotecan,GM-CSF
Description: 1. Dose climbing stage design (n=12) :~   Surufatinib: Oral, 3w.The initial dose of 250mg/ day (n=6) : If 2 out of 6 patients developed \> DLT in the first treatment cycle, the exploratory dose was 200 mg/ day; if ≤2 out of 6 patients developed DLT, the exploratory dose was 300mg/ day (n=6);At the next dose phase, if 2 out of 6 patients with \> developed DLT, the previous dose was recommended or the study was terminated;If no more than 2 out of 6 patients developed DLT, the dose was the recommended dose；PD-1,200mg, iv,D1, 3w；Irinotecan: 200mg/㎡, iv, D1, 3w；GM-CSF,D2, D3, D4, D5, D6 and D7 in the first week of each cycle ；~2. Dose expansion phase design(n=36):~   1. Surufatinib: Oral, 3w. the dose was set according to the recommended dose in the dose climbing stage;~  2. PD-1(Camrelizumab) : 200mg, iv,D1, 3w;~  3. Irinotecan: 200mg/㎡, iv, D1, 3w;~  4. GM-CSF: continuous administration of D2, D3, D4, D5, D6 and D7 in the first week of each cycle, 5ug/kg once per body weight, once a day, 3w.
Study: NCT06007716

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reflexology massage
Description: 5 minutes of classic message on the left foot, 15 minutes of reflexology message, and 5 minutes of classic message on the right foot, 15 minutes of reflexology message, a total of 40 minutes of massage. 30 minutes after the massage, evaluation was recorded with the Vital Signs Registration Form, McGill Pain Scale Short Form, State Anxiety Inventory, General Comfort Scale Short Form, and Fatigue and Quality Sleep Visual Comparison Scale. Thus, reflexology massage is performed once a day for each patient for 2 consecutive days, for a total of 2 sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo massage
Description: Placebo reflexology massage was applied to each foot for 20 minutes, for a total of 40 minutes.30 minutes after the massage, evaluation was recorded with the Vital Signs Registration Form, McGill Pain Scale Short Form, State Anxiety Inventory, General Comfort Scale Short Form, and Fatigue and Quality Sleep Visual Comparison Scale. Thus, Placebo massage is performed once a day for each patient for 2 consecutive days, for a total of 2 sessions.
Study: NCT05309018

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.
Study: NCT05569018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended group transversal protocol (BLGr-TP)
Description: It will consist in the administration of a transdiagnostic treatment protocol composed by 16 modules focused on regulating both negative and positive affect. The intervention will be administered over a 16-week period. Face-to-face group sessions will be combined with autonomous work of patients through a web platform where they will find the contents of the program. The groups will have 6-10 patients, who will attend a total of 8 face-to-face sessions of 2 hours long each one. The online part of the treatment (self-applied Online Transversal Protocol) will consist in working the contents exposed in the face-to-face sessions during between-sessions period (2 weeks). It is an interactive program with multimedia elements (videos, images,...) that allows people to perform the modules from home and at their own pace. In addition, the program is characterized by its ease of use, presenting an agile navigation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face group transversal protocol (FFGr-TP)
Description: It will consist in the administration of the transdiagnostic treatment protocol through the 16 modules focused on regulating both negative and positive affect. The intervention will be carried out in face-to-face group format and it will be administered during a 16-week period. The groups will have between 6 to 10 patients, who will attend a total of 16 face-to-face sessions of 2 hours long each one. During between-sessions period (1 week), patients will work the content of the modules exposed in the face-to-face sessions through tasks for home (traditional paper format).
Study: NCT05433779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neosense Umbilical Catheter
Description: The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
Study: NCT05546229

Intervention type: PROCEDURE
Intervention: Microneedle based interstitial fluid collection
Description: Interstitial fluid will be collected from the skin using microneedles and suction.

Intervention type: PROCEDURE
Intervention: Microneedle based interstitial fluid collection
Description: Interstitial fluid will be collected from the skin using microneedles and suction.

Intervention type: PROCEDURE
Intervention: Microneedle based interstitial fluid collection
Description: Interstitial fluid will be collected from the skin using microneedles and suction.
Study: NCT05248139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative delivery of medication, Kenalog (Triamcinolone)
Description: Subconjunctival triamcinolone acetonide 4 mg (0.4 mL of 10 mg/mL solution), single-dose injected 6-8 mm inferior to the inferior limbus with a bent 27-gauge needle at completion of cataract surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical post-operative eyedrops, Prednisolone acetate
Description: Standard of care Presnisolone acetate 1% ophthalmic drop taper: 4 times per day for first week, then tapering one drop per week for 3 additional weeks. Discontinued after 4 weeks.
Study: NCT05927363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic educational consolidation program in Phase 3 of cardiac rehabilitation associating a patient & caregiver partnership
Description: In the experimental group, patients benefit from the usual management as part of the phase 2 post-CR follow-up, with the provision of an information booklet on the benefits of physical activity, and a telephone contact in the event of any questions. In addition, they benefit from the Consolidation therapeutic education program in phase 3 of CR associating a patient \& caregiver partnership, which consists of two teleconsultation sessions at 2 and 4 months, followed by a remote group education workshop co-facilitated by the patient and caregiver partnership at 5 months.~Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation at 2 months
Description: Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation at 4 months
Description: Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote group education workshop
Description: This remote workshop will be co-facilitated by the patient and caregiver partnership at 5 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of self-questionnaires: IPAQ, EMAPS, the Exercise Confidence Survey, EQ-5D-5L and the Mediterranean diet adherence score.
Description: Patients are then randomly assigned to either the control group (usual management) or the experimental group (management with Patient and Caregiver partnership).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minute walk test and administers the modified Borg scale at its conclusion.
Description: What is a modified Borg scale? The Modified Borg Dyspnea Scale is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and is routinely administered following a six-minute walking test, one of the most common and frequently used measures to assess disease severity in patients with pulmonary arterial hypertension. Upon conclusion of the 6-minute walking test, the modified Borg scale will be recorded.
Study: NCT06149416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Masimo RD SET SpO2 Adhesive Sensors
Description: Masimo RD SET SpO2 Adhesive Sensors, Adult (4000 Adt), Adult \& Neonate (4003 Neo)
Study: NCT05139004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium In 111-DOTA-Basiliximab
Description: Given IV
Study: NCT05811546

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemical staining for DNMT1 and EZH2
Description: Immunohistochemical staining for DNMT1 and EZH2 using rabbit monoclonal/polycolonal antibodies with immunoperoxidase staining will be used as a visualization method. Antibodies dilutions, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions.
Study: NCT05139004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation
Description: Undergo TMLI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Undergo TMLI
Study: NCT05927363

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biological check-up
Description: This check-up includes total cholesterol, LDL, HDL, triglycerides, HbA1c.
Study: NCT05139004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Basiliximab
Description: Given IV
Study: NCT05734651

Intervention type: DEVICE
Intervention: PROMIS Stem
Description: Primary Total Hip Arthroplasty with the PROMIS Stem (Fa. Falcon Medical, Mödling, Austria)
Study: NCT05816109

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: superficial cervical block
Description: After anesthesia and surgical procedures, bilateral superficial cervical plexus block will be applied to the lower border of the sternocleidomastoid muscle, accompanied by ultrasonography. After cleaning the area with povidone iodine before the block, the sternocleidomastoid muscle and carotid artery and other vascular structures are determined using a linear ultrasound probe. Local anesthetic will be administered between the lower border of the sternocleidomastoid muscle and the upper border of the prevertebral fascia with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection method with saline before local anesthesia is given. After the location of the needle is confirmed, 2 ml of saline will be injected, followed by 10 ml of 0.5% bupivacaine. The deep cervical fascia of the superficial lamina will appear to open.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: without superficial cervical block
Description: patients who underwent anterior cervical surgery and did not undergo superficial cervical block
Study: NCT05927363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: An accelerometer is given to the patient, with instructions to wear it for 7 days following the visit (it will then be returned by post).Pre-stamped bubble envelopes are given to the patient to return their accelerometer to the measurement points specified in the follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of a logbook
Description: The patient is given a logbook for daily monitoring of non-measurable physical activities, treatments and medical procedures carried out, as well as any intercurrent events.
Study: NCT06349668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal analgesia with morphine and bupivacaine
Description: single shot spinal analgesia with 0.2-0.3 mg morphine and 10-20 mg bupivacaine before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine infusion
Description: intraoperative intravenous infusion of lidocaine at a rate of 2 mg/kg/t (Ideal Body Weight)
Study: NCT04887896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GS500
Description: Device: GS500

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Device: Placebo
Study: NCT05688020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid will be injected as part of the injectate during endoscopic resection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine injection
Description: Epinephrine will be injected as part of the standard injectate used during endoscopic resection.
Study: NCT06384755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Honest Open Proud program
Description: The HOP program involves peer facilitated sessions, in which different stigma and disclosure related topics are introduced to the group, relevant tasks are completed individually, followed by group or two-and-two discussions related to the following topics: week 1 = pros and cons with disclosure, week 2 = different ways of disclosing, week 3 = formulating individual decisions of disclosure, week 6 = evaluating disclosure or non-disclosure in practice.
Study: NCT06284733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration plus conservative care
Description: Whole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform. This method was used in rehabilitation to improve muscle function, joint stability, balance control and to reduce the risk of falling.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration plus conservative care
Description: Whole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform. This method was used in rehabilitation to improve muscle function, joint stability, balance control and to reduce the risk of falling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative care
Description: 1. Stretching and ROM exercises daily to make sure that the patient can straighten hip; this makes walking, and even lying in bed, more comfortable.~2. Resting hip on a pillow, as this promotes a hip flexion contracture~3. A pillow between legs, as this lengthens the inner thigh muscle that helps to keep legs together while walking, and shortens the outer thigh muscles so that walking and standing with feet apart.~4. Regular skin care.~5. Regular prosthetic care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative care
Description: 1. Stretching and ROM exercises daily to make sure that the patient can straighten hip; this makes walking, and even lying in bed, more comfortable.~2. Resting hip on a pillow, as this promotes a hip flexion contracture~3. A pillow between legs, as this lengthens the inner thigh muscle that helps to keep legs together while walking, and shortens the outer thigh muscles so that walking and standing with feet apart.~4. Regular skin care.~5. Regular prosthetic care.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conservative care
Description: 1. Stretching and ROM exercises daily to make sure that the patient can straighten hip; this makes walking, and even lying in bed, more comfortable.~2. Resting hip on a pillow, as this promotes a hip flexion contracture~3. A pillow between legs, as this lengthens the inner thigh muscle that helps to keep legs together while walking, and shortens the outer thigh muscles so that walking and standing with feet apart.~4. Regular skin care.~5. Regular prosthetic care.
Study: NCT06160492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid
Description: Patients were randomly assigned to 5-aminolevulinic acid (20 mg/kg bodyweight）Those randomly allocated to 5-aminolevulinic acid were scheduled to receive freshly prepared solutions of 5-aminolevulinic acid orally 3 h (range 2-4) before induction of anaesthesia. Solutions were prepared by dissolving the contents of a vial (1·5 g) in 50 mL of drinking water.
Study: NCT06294847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolvan
Description: single dose of Ursolvan® (10mg/kg) orally within 24 hours before the surgical intervention, followed by a daily dose of 10mg/kg in two divided doses for 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a single dose of placebo orally within 24 hours before the surgical intervention, followed by two doses per day for 30 days